References
- Glickman, M. H. and Ciechanover, A. : The ubiquitinproteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373 (2002). https://doi.org/10.1152/physrev.00027.2001
- Voges, D., Zwickl, P. and Baumeister, W. : The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015 (1999). https://doi.org/10.1146/annurev.biochem.68.1.1015
- Nalepa, G., Rolfe, M. and Harper, J. W. : Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug. Discov. 5, 596 (2006). https://doi.org/10.1038/nrd2056
- Richardson, P. G. and Mitsiades, C. : Bortezomib: proteasome inhibition as an effective anticancer therapy. Future. Oncol. 1, 161 (2005). https://doi.org/10.1517/14796694.1.2.161
- Roccaro, A. M., Hideshima, T., Richardson, P. G., Russo, D., Ribatti, D., Vacca, A., Dammacco, F. and Anderson, K. C. : Bortezomib as an antitumor agent. Curr. Pharm. Biotechnol. 7, 441 (2006). https://doi.org/10.2174/138920106779116865
- Kraus, M., Ruckrich, T., Reich, M., Gogel, J., Beck, A., Kammer, W., Berkers, C. R., Burg, D., Overkleeft, H., Ovaa, H. and Driessen, C. : Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21, 84 (2007). https://doi.org/10.1038/sj.leu.2404414
- Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P. and Anderson, K. C. : A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609 (2003). https://doi.org/10.1056/NEJMoa030288
- Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M. and Nabeshima, Y. : An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313 (1997). https://doi.org/10.1006/bbrc.1997.6943
- Kobayashi, M. and Yamamoto, M. : Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid. Redox. Signal. 7, 385 (2005). https://doi.org/10.1089/ars.2005.7.385
- Li, W. and Kong, A. N. : Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 48, 91 (2009). https://doi.org/10.1002/mc.20465
- Hayes, J. D., McMahon, M., Chowdhry, S. and Dinkova- Kostova, A. T. : Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox. Signal. 13, 1713 (2010). https://doi.org/10.1089/ars.2010.3221
- Kwak, M. K. and Kensler, T. W. : Targeting NRF2 signaling for cancer chemoprevention. Toxicol. Appl. Pharmacol. 244, 66 (2010). https://doi.org/10.1016/j.taap.2009.08.028
- Hayes, J. D. and McMahon, M. : NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends. Biochem. Sci. 34, 176 (2009). https://doi.org/10.1016/j.tibs.2008.12.008
- Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M. I., Kobayashi, A., Yokoyama, S. and Yamamoto, M. : Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell. 21, 689 (2006). https://doi.org/10.1016/j.molcel.2006.01.013
- Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., Brock, M. V. and Biswal, S. : Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006). https://doi.org/10.1371/journal.pmed.0030420
- Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M. and Hirohashi, S. : Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358 (2008). https://doi.org/10.1053/j.gastro.2008.06.082
- Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M. and Hirohashi, S. : Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105, 13568 (2008). https://doi.org/10.1073/pnas.0806268105
- Shim, G. S., Manandhar, S., Shin, D. H., Kim, T. H. and Kwak, M. K. : Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic. Biol. Med. 47, 1619 (2009). https://doi.org/10.1016/j.freeradbiomed.2009.09.006
- Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., Gabrielson, E., Feinstein, E. and Biswal, S. : RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer. Res. 68, 7975 (2008). https://doi.org/10.1158/0008-5472.CAN-08-1401
- Manandhar, S., Choi, B. H., Ryoo, I. G., Kang, S. J., Kim, J. A., Choi, H. G., Park, P. H. and Kwak, M. K. : NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity. (Submitted).
- Cho, J. M., Manandhar, S., Lee, H. R., Park, H. M. and Kwak, M. K.: Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer. Lett. 260, 96 (2008). https://doi.org/10.1016/j.canlet.2007.10.022
- Fuchs, D., Berges, C., Opelz, G., Daniel, V. and Naujokat, C. : Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J. Cell. Biochem. 103, 270 (2008). https://doi.org/10.1002/jcb.21405
- Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J. W., Ylstra, B., Peters, G. J., Kaspers, G. L., Dijkmans, B. A., Scheper, R. J. and Jansen, G. : Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489 (2008). https://doi.org/10.1182/blood-2007-08-104950
- Busse, A., Kraus, M., Na, I. K., Rietz, A., Scheibenbogen, C., Driessen, C., Blau, I. W., Thiel, E. and Keilholz, U. : Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer. 112, 659 (2008). https://doi.org/10.1002/cncr.23224
- Nguyen, T., Sherratt, P. J., Huang, H. C., Yang, C. S. and Pickett, C. B. : Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J. Biol. Chem. 278, 4536 (2003). https://doi.org/10.1074/jbc.M207293200
- Sekhar, K. R., Soltaninassab, S. R., Borrelli, M. J., Xu, Z. Q., Meredith, M. J., Domann, F. E. and Freeman, M. L. : Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. Biochem. Biophys. Res. Commun. 270, 311 (2000). https://doi.org/10.1006/bbrc.2000.2419
- Maines, M. D. : The heme oxygenase system: update 2005. Antioxid. Redox. Signal. 7, 1761 (2005). https://doi.org/10.1089/ars.2005.7.1761
- Chen, J. and Regan, R. F. : Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury. Curr. Neurovasc. Res. 2, 189 (2005). https://doi.org/10.2174/1567202054368344
- Wu, W. T., Chi, K. H., Ho, F. M., Tsao, W. C. and Lin, W. W. : Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition. Biochem. J. 379, 587 (2004). https://doi.org/10.1042/BJ20031579
- Yamamoto, N., Izumi, Y., Matsuo, T., Wakita, S., Kume, T., Takada-Takatori, Y., Sawada, H. and Akaike, A. : Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection. J. Neurosci. Res. 88, 1934 (2010).